Gold: Rebound tests major resistance band – Societe Generale
Societe Generale analysts note that Gold has held the $3,930/3,885 support zone linked to the November 2025 low and rebounded sharply. Prices are approaching a descending trend line near $4,300, but the bank sees no clear signs of a large bounce yet, with the confluence of the 50‑DMA and 200‑DMA at $4,380/4,480 flagged as a key hurdle.
Support defended, resistance overhead
"Gold successfully defended the interim support zone at $3,930/3,885, corresponding to the low of November 2025, and has staged a swift rebound."
"It is now approaching the descending trend line drawn since March, currently situated near $4,300."
"Signals of a large bounce are not yet visible."
"It will be important to monitor whether Gold can establish a base and gradually attempt a reversal."
"Confluence of the 50-DMA and 200-DMA around $4,380/4,480 may act as a significant hurdle."
(This article was created with the help of an Artificial Intelligence tool and reviewed by an editor.)
Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.
You may also like
The "Outlier" Investment Art in the New Era of Berky
Chevron (CVX.US) explores alternative hedging for Middle East supply disruptions: targets Argentina and the Mediterranean to drive global LNG growth, seeks deal with India
Chevron is focusing on Argentina and the Mediterranean region, seeking global growth in liquefied natural gas, and plans to reach an agreement with India.
Energy and food price pressures intensify, potentially triggering an inflation rebound! The Bank of England may struggle to remain "calm" as market rate hike bets surge
The upward pressure on energy prices caused by the unresolved Middle East war is mounting. New risks are also approaching, which may keep inflation above the Bank of England’s 2% target for most of next year.
AstraZeneca (AZN.US) Breast Cancer Drug Etcamah Faces Setback in Phase III Clinical Trial, Potentially Impacting Billions in Sales
Bloomberg Intelligence analyst John Murphy stated that the setback in AstraZeneca's breast cancer drug trial could reduce sales in 2035 by $2.6 billion to $3.8 billion.
Crypto prices
More
